A recent retrospective study found that performing Chronic Total Occlusion Percutaneous Coronary Intervention (CTO-PCI) ...

Aplagon is also planning for 2026 a Phase 2 clinical trial for arteriovenous fistula (AVF) maturation failure in Europe, following the successful completion of its Phase 1 AVF trial. The study ...

Helsinki, Finland Saturday, March 14, 2026, 18:00 Hrs [IST] ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Stenting guided by intravascular imaging rather than angiography is linked to a lower risk for target vessel failure in ...

Aplagon has dosed the first patient in its phase 2a HEALING clinical trial evaluating APAC, a first‑in‑class treatment for thrombo‑inflammatory diseases, in people with peripheral arterial occlusive ...

A recent clinical study has demonstrated that a novel "floating aortic wire" technique successfully prevents deep guide engagement in 92% of cases during complex cardiac procedures. This ...

Three-year outcomes from the PERFORMANCE II trial studying the Neuroguard Integrated Embolic Protection (IEP) 3-in-1 Carotid Sten ...

Final follow-up from the trial shows durable protection against TLF, especially in chronic total occlusions and diffuse long ...

The vast majority of patients presenting with type 1 NSTEMI undergo invasive coronary angiography in the US, with most ...

For the 11 million Americans living with angina, chronic chest pain caused by a lack of blood flow to the heart muscle can ...

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best stocks that will always grow. Intuitive Surgical, Inc. (NASDAQ:ISRG) announced on March 2 the completion of its acquisition of the da Vinci ...